Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
This guidance has been re-issued after a change to the commercial arrangements in July 2016. This change does not affect abiraterone’s cost effectiveness. Recommendation 1.1, sections 2.3 and 5.4 and the summary of appraisal committee key conclusions table have been updated.
We reviewed the evidence in December 2017. We found nothing new that affects the recommendations in this guidance. We are incorporating the guidance into the update of NICE’s clinical guideline on prostate cancer (CG175).
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.